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Meta-analyses with rare events
should use adequate methods
To the Editor:
With great interest we read the meta-analy-
sis of randomized clinical trials of Takagi
and associates1 on postoperative stroke
risk in off-pump and on-pump coronary ar-
tery bypass grafting. Their work is a wel-
come update of the most recent meta-
analysis on this topic by Sedrakyan and
colleagues.2
Contrary to Sedrakyan and associates,
however, Tagaki and colleagues do not
find a significant difference between off-
and on-pump surgery (relative risk [95%
confidence interval]: 0.60 [0.34–1.06];
P5 .08), whereas Sedrakyan’s group found
0.50 [0.27,0.93; P 5 .03] for the relative
risk. As an explanation, Tagaki’s group
points to the methodical difficulties of deal-
ing with studies reporting no events in both
treatment groups. Whereas Sedrakyan and
associates removed these studies from anal-
ysis, Tagaki and colleagues obviously used
a ‘‘0.5-correction’’ rule, where 0.5 is added
to the number of events as well as to the
number of nonevents in both groups (at
least, this is how we were able to reproduce
their results).
However, we object to both ideas of
dealing with studies with zero events. Inas-
much as those studies point to equal risk
for both treatments (as Tagaki’s group noted
correctly), deleting them, as Sedrakyan’s
group did, would probably overestimate
the treatment effect. On the contrary, using
the ‘‘0.5-correction’’ rule, as Tagaki and
colleagues did, adds 13 pseudoevents in
the off-pump group and another 13 in the
on-pump group. Thus, the analysis is per-
formed with 59 pseudo-observed, instead
of 33 actually observed, events, rendering
the analysis also somewhat dubious.
We would rather recommend methods
that adequately account for studies with
zero observations. These methods have
been proposed,3 are straightforward exten-
sions of the familiar Mantel-Haenszel
method,4 and standard software (eg, SAS
PROC FREQ, CMH option, code is avail-
able from the authors on request) is available
for computation. We reanalyzed the Tagaki
data* and found an estimated relative risk
of 0.376 [0.175, 0.807; P 5 .0091]. Note
that this value compares very closely with
the relative risk from the simple and most in-
tuitive analysis performed by collapsing the
data from the 32 studies into a simple 4-fold
table: 0.377 [0.176, 0.810; P 5 .0092].
We therefore conclude that there is still
significant evidence that the off-pump
method is superior to the on-pump method
in reducing postoperative stroke risk after
coronary bypass grafting.
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*Note a printing error in Table 1 of the study by
Tagaki and associates.1 The number of random-
ized patients in the off-pump group from the
Lonn study should be ‘‘15,’’ not ‘‘60.’’ We per-
formed all analyses with the corrected data set.
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Letters to the EditorFactors predicting poor survival
after resection of stage IA
non–small cell lung cancer
To the Editor:
Wehave readwith interest the paper byChang
and associates.1 Interestingly, we observe that
the factors considered to predict poor survival
after resection of stage IA non–small cell lung
cancer (NSCLC) still remain tumor size, gen-
der, age, and extent of resection.The Journal of Thoracic and CardiovascuIt is true, in fact, that lung cancer staging
currently rests on histopathologic and clini-
cal criteria that have only limited power to
predict relapse and survival. A major effort
to improve the control of NSCLC entails
the use of molecular profiling to characterize
tumors and provide accurate predictions of
the outcome after standard or novel treat-
ments. Moreover, molecular profiling, as
we2 already discussed in 2003, could really
provide an entirely new classification sys-
tem.
Recently, one study has demonstrated the
potential clinical applications of gene expres-
sion profiling in a cohort of 89 patients with
early-stage NSCLC in predicting the risk of
disease recurrence.3 The authors evaluated
the predictor in two independent groups of
25 patients from the American College of
Surgeons Oncology Group Z0030 study
and 84 patients from the Cancer and Leuke-
mia Group B 9761 study. The overall
predictive accuracy was 72% and 79%, re-
spectively. The predictor also identified
a subgroup of patients with stage IA disease
who were at high risk for recurrence and
who might be best treated by adjuvant che-
motherapy. Additionally, an 11-gene expres-
sion signature associated with ‘‘stem cell-
ness’’ was found to divide patients with dif-
ferent cancers, including NSCLC, into
good- and poor-prognosis groups; however,
this stem cell–associated signature has not
been validated or further studied inNSCLC.4
On a pragmatic basis, a rigorous prospective
approach, using training and testing cohorts,
to study molecular prognostic markers could
improve chances of identifying true molecu-
lar prognostic markers that may be reliably
applied to clinical practice. Potential research
goals may include the following (1): identify
molecular tissue, blood, and plasma markers
(ie, gene expression profile, genetic poly-
morphism, genetic/epigenetic alterations,
plasma proteomic) predictive of survival, re-
currence, and metastasis development in
patients with NSCLC; (2) establish charac-
teristics of precursor lesions and the field of
cancerization phenomenon in NSCLC path-
ogenesis by smoking status, gender, and eth-
nic background; (3) establish molecular
markers to discover occult micrometastasis
in lymph nodes (sentinel lymph node); (4)
evaluate the presence of ‘‘stem-cancer cells’’;
(5) identify molecular tissue and blood
markers to predict response to adjuvant che-
motherapy; (6) identify molecular markers
predictive of response to chemotherapeuticlar Surgery c Volume 136, Number 1 241
Letters to the EditorFigure 1. Application of molecular biol-
ogy to refine the assessment of risk and
guide the use of adjuvant chemotherapy
in stage IA non–small cell lung cancer
(NSCLC).Focus on the Thoracoscore
To the Editor:
It is with great interest that we read the article
entitled ‘‘Thoracoscore predicts midterm
mortality in patients undergoing thoracic
surgery.’’1 The authors’ findings and conclu-
sions concur perfectly with those of our
initial main work, which first created and
proposed the use of the Thoracoscore.2
However, we would like to emphasize 2
points that we consider to be important.
First, one of our concerns is the reliability
of anymodification in the French scoring sys-
tem (Thoracoscore), as was done with the
dyspnea score in the present study. This point
is particularly crucial. Effectively, our initial
aim was to develop a self-assessment system
based on a large database reflecting current
practices in adult thoracic surgery. Nine pre-
dictors were selected from the database. Their
definitions, which are consistent throughout
the world and particularly in North American
systems, were objective enough to develop
a reliable scoring system that could be used
by all thoracic surgeons and for all types of
thoracic procedures. This is why we think
that theThoracoscore canbeusedasa relevant
yardstick for mortality. Moreover, the French
scoring system, built onwell-defined risk fac-
tors, is alsouser friendlyand imposesminimal
demands on medical time. At this point,
a word of caution is essential: the condition
under which such a system is used needs to
be considered. The Thoracoscore was con-
structed so as to deal with the problem of
a missing item. Indeed, in the case of 1 or
more items missing from the 9 predictors se-
lected, the Thoracoscore gives a range (mini-
mum and maximum values) of estimated
mortality rather than a percentage of predic-
tivemortality. Thus it can be used easily, as is.
Second, why is the Thoracoscore a reli-
able tool, and how can it be used world-
wide? The Thoracoscore is reliable
because it comes from a national electronic
prospective database created by a national
society of thoracic and cardiovascular sur-
gery. Indeed, the French database Epithor,
created in 2002 on behalf of the French So-
ciety of Thoracic and Cardiovascular Sur-
gery, includes anonymous information
from two thirds of all thoracic surgery pro-
cedures performed in France each year
(.60,000 from 59 centers: 37 public and
15 private). Each center is free to compare
its statistics and results with the national
means. It can also be used to register pa-
tients for administrative hospital files.
In addition, Epithor is now mandatory for
the accreditation of thoracic surgery depart-
ments. Therefore the Thoracoscore tool can
be transposed to any organization (country/or targeted therapeutic agents at timeof recur-
rence. Therefore, development of a tissue and
blood (serum, plasma, and circulating cells)
bank with specimens obtained in clinical tri-
als, including detailed prospective collected
clinical data, is of the utmost importance.
This new phase of target profiling and
agent-specific profiling will probably require
an algorithm that would include genomic,
proteomic, clinical, and imaging factors.
Patients with early-stage NSCLC will be
assigned to particular drugs on the basis of
the molecular characteristics of their tumors.
Then the development of drugs for the treat-
ment of NSCLC will be focused on person-
alized therapy.
Figure 1 outlines a possible application
of molecular biology to refine the assess-
ment of risk and guide the use of adjuvant
chemotherapy in stage IA NSCLC.
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